[1] Hoffmann, S., Batz, B.M. and Morris Jr., J.G. (2012) Annual Cost of Illness and Quality-Adjusted Life Year Losses in the United States Due to 14 Foodborne Pathogens. Journal of Food Protection, 75, 1292-1302.
http://dx.doi.org/10.4315/0362-028X.JFP-11-417
[2] Dubey, J.P. and Jones, J.L. (2008) Toxoplasma gondii Infection in Humans and Animals in the United States. International Journal for Parasitology, 38, 1257-1278.
http://dx.doi.org/10.1016/j.ijpara.2008.03.007
[3] Kieffer, F. and Wallon, M. (2013) Congenital Toxoplasmosis. Handbook of Clinical Neurology, 112, 1099-1101.
http://dx.doi.org/10.1016/B978-0-444-52910-7.00028-3
[4] Olariu, T.R., Remington, J.S., McLeod, R., Alam, A. and Montoya, J.G. (2011) Severe Congenital Toxoplasmosis in the United States: Clinical and Serologic Findings in Untreated Infants. Pediatric Infectious Disease Journal, 30, 1056-1061.
http://dx.doi.org/10.1097/INF.0b013e3182343096
[5] Remington, J.S., Thulliez, P. and Montoya, J.G. (2004) Recent Developments for Diagnosis of Toxoplasmosis. Journal of Clinical Microbiology, 42, 941-945.
http://dx.doi.org/10.1128/JCM.42.3.941-945.2004
[6] Wong, S.-Y. and Remington, J.S. (1994) Toxoplasmosis in Pregnancy. Clinical Infectious Diseases, 18, 853-861.
http://dx.doi.org/10.1093/clinids/18.6.853
[7] Mead, P.S., Slutsker, L., Dietz, V., et al. (1999) Food-Related Illness and Death in the United States. Emerging Infectious Diseases, 5, 607-625.
http://dx.doi.org/10.3201/eid0505.990502
[8] Pereira, K.S., Franco, R.M.B. and Leal, D.A.G. (2010) Transmission of Toxoplasmosis (Toxoplasma gondii) by Foods. Advances in Food and Nutrition Research, 60, 1043-4526.
http://dx.doi.org/10.1016/S1043-4526(10)60001-0
[9] Jones, J.L., Kruszon-Moran, D., Wilson, M., McQuillan, G., Navin, T. and McAuley, J.B. (2001) Toxoplasma gondii Infection in the United States: Seroprevalence and Risk Factors. The American Journal of Epidemiology, 154, 4, 357-365.
http://dx.doi.org/10.1093/aje/154.4.357
[10] Brown, A.S., Schaefer, C.A., Quesenberry Jr., C.P., Liu, L., Babulas, V.P. and Susser, E.S. (2005) Maternal Exposure to Toxoplasmosis and Risk of Schizophrenia in Adult Offspring. The American Journal of Psychiatry, 162, 767-773.
http://dx.doi.org/10.1176/appi.ajp.162.4.767
[11] Bachmann, S., Schroder, J., Bottmer, C., Torrey, E.F. and Yolken, R.H. (2005) Psychopathology in First-Episode Schizophrenia and Antibodies to Toxoplasma gondii. Psychopathology, 38, 87-90.
http://dx.doi.org/10.1159/000085349
[12] Wang, H.L., Wang, G.H., Li, Q.Y., Shu, C., Jiang, M.S. and Guo, Y. (2006) Prevalence of Toxoplasma Infection in First-Episode Schizophrenia and Comparison between Toxoplasma-Seropositive and Toxoplasma-Seronegative Schizophrenia. Acta Psychiatrica Scandinavica, 114, 40-48.
http://dx.doi.org/10.1111/j.1600-0447.2006.00780.x
[13] Cortina-Borja, M., Tan, H.K., Wallon, M., Paul, M., Prusa, A., Buffolano, W., et al. (2010) Prenatal Treatment for Serious Neurological Sequelae of Congenital Toxoplasmosis: An Observational Prospective Cohort Study. PLoS Medicine, 7, Article ID: e1000351.
http://dx.doi.org/10.1371/journal.pmed.1000351
[14] Berrebi, A., Assouline, C., Bessieres, M.H., Lathière, M., Cassaing, S., Minville, V. and Ayoubi, J.M. (2010) Long-Term Outcome of Children with Congenital Toxoplasmosis. The American Journal of Obstetrics and Gynecology, 203, 552.e1-552.e6.
http://dx.doi.org/10.1016/j.ajog.2010.06.002
[15] Habib, F.A. (2008) Post-Treatment Assessment of Acute Toxoplasma Infection during Pregnancy. Journal of Obstetrics and Gynaecology, 28, 593-595.
http://dx.doi.org/10.1080/01443610802344332
[16] Julliac, B., Theophile, H., Begorre, M., Richez, B. and Haramburu, F. (2010) Side Effects of Spiramycin Masquerading as Local Anesthetic Toxicity during Labor Epidural Analgesia. International Journal of Obstetric Anesthesia, 19, 331-332.
http://dx.doi.org/10.1016/j.ijoa.2010.03.002
[17] Petersen, E. and Schmidt, D.R. (2003) Sulfadiazine and Pyrimethamine in the Postnatal Treatment of Congenital Toxoplasmosis: What Are the Options? Expert Review of Anti-Infective Therapy, 1, 175-182.
http://dx.doi.org/10.1586/14787210.1.1.175
[18] Bessieres, M.H., Berrebi, A., Cassaing, S., Fillaux, J., Cambus, J.P., Berry, A., Assouline, C., Ayoubi, J.M. and Magnaval, J.F. (2009) Diagnosis of Congenital Toxoplasmosis: Prenatal and Neonatal Evaluation of Methods Used in Toulouse University Hospital and Incidence of Congenital Toxoplasmosis. Memorias do Instituto Oswaldo Cruz, 104, 389-392.
http://dx.doi.org/10.1590/S0074-02762009000200038
[19] Oz, H.S. and Tobin, T. (2012) Atovaquone Ameliorates Gastrointestinal Toxoplasmosis Complications in a Pregnancy Model. Medical Science Monitor, 18, 337-345.
http://dx.doi.org/10.12659/MSM.883342
[20] Oz, H.S., Hughes, W.T. and Rehg, J.E. (1999) Rat Model for Dual Opportunistic Pathogen Prophylaxis: Cryptosporidium Parvum and Pneumocystis carinii. Laboratory Animal Science, 49, 331-334.
[21] Hudson, A.T., Dickins, M., Ginger, C.D., Gutteridge, W.E., Holdich, T., Hutchinson, D.B., Pudney, M., Randall, A.W. and Latter, V.S. (1991) 566C80: A Potent Broad Spectrum Anti-Infective Agent with Activity against Malaria and Opportunistic Infections in AIDS Patients. Drugs under Experimental and Clinical Research, 17, 427-435.
[22] Hughes, W.T. and Oz, H.S. (1995) Successful Prevention and Treatment of Babesiosis with Atovaquone. Journal of Infectious Diseases, 172, 1042-1046.
http://dx.doi.org/10.1093/infdis/172.4.1042
[23] Oz, H.S. and Westlund, H.K. (2012) Human Babesiosis: An Emerging Transfusion Dilemma. International Journal of Hepatology, 2012, Article ID: 431761.
http://dx.doi.org/10.1155/2012/431761
[24] Assis, R.C.L., Luns, F.D., Beletti, M.E., Assis, R.L., Nasser, N.M., Faria, E.S.M. and Cury, M.C. (2010) Histomorphometry and Macroscopic Intestinal Lesions in Broilers Infected with Eimeria acervulina. Veterinary Parasitology, 168, 185-189.
http://dx.doi.org/10.1016/j.vetpar.2009.11.017
[25] Granstrom, D.E. and Tobin, T. (1999) Treatment of EPM Formulations and Methods to Treat and Prevent Equine Protozoal Myeloencephalitis. US Patent No. 5883095.
[26] Dirikolu, L., Lehner, F., Nattrass, C., et al. (1999) Diclazuril in the Horse: Its Identification and Detection and Preliminary Pharmacokinetics. Journal of Veterinary Pharmacology and Therapeutics, 22, 374-379.
http://dx.doi.org/10.1046/j.1365-2885.1999.00232.x
[27] Hackstein, J.H.P., Mackenstedt, U., Mehlhorn, H., Meijerink, J.P.P., Schubert, H. and Leunissen, J.A.M. (1995) Parasitic Apicomplexans Harbor a Chlorophyll a-D1 Complex, the Potential Target for Therapeutic Triazines. Parasitology Research, 81, 207-216.
[28] Oz, H.S. and Tobin, T. (2014) Diclazuril Protects against Maternal Gastrointestinal Syndrome and Congenital Toxoplasmosis. International Journal of Clinical Medicine, 5, 93-101.
http://dx.doi.org/10.4236/ijcm.2014.53017
[29] Ajzenberg, D., Cogne, N., Paris, L., Bessières, M.H., Thulliez, P., Filisetti, D., Pelloux, H., Marty, P. and Dardé, M.L. (2002) Genotype of Toxoplasma gondii Isolates Associated with Human Congenital Toxoplasmosis, and Correlation with Clinical Findings. Journal of Infectious Diseases, 186, 684-689.
http://dx.doi.org/10.1086/342663
[30] Howe, D.K., Honore, S., Derouin, F. and Sibley, L.D. (1997) Determination of Genotypes of Toxoplasma gondii Strains Isolated from Patients with Toxoplasmosis. Journal of Clinical Microbiology, 35, 1411-1414.
[31] Oz, H.S., Ebersole, J.L. and de Villiers, W.J.S. (2011) The Macrophage Pattern Recognition Scavenger Receptors SR-A and CD36 Protect against Microbial Induced Pregnancy Loss. Inflammation Research, 60, 93-97.
http://dx.doi.org/10.1007/s00011-010-0241-1
[32] Oz, H.S., Chen, T.S. and Nagasawa, H. (2007) Comparative Efficacies of 2 Cysteine Prodrugs and a Glutathione Delivery Agent in a Colitis Model. Translational Research, 150, 122-129.
http://dx.doi.org/10.1016/j.trsl.2006.12.010
[33] Oz, H.S., Chen, T. and de Villiers, W.J.S. (2013) Green Tea Polyphenols and Sulfasalazine Have Parallel Anti-Inflammatory Properties in Colitis Models. Frontiers in Immunology, 132, 1-103.
http://dx.doi.org/10.3389/fimmu.2013.00132
[34] Oz, H.S., Im, H.J., Chen, T.S., de Villiers, W.J.S. and McClain, C.J. (2006) Glutathione-Enhancing Agents Protect against Steatohepatitis in a Dietary Model. Journal of Biochemical and Molecular Toxicology, 20, 39-47.
http://dx.doi.org/10.1002/jbt.20109
[35] Pappas, G., Roussos, N. and Falagas, M.E. (2009) Toxoplasmosis Snapshots: Global Status of Toxoplasma gondii Seroprevalence and Implications for Pregnancy and Congenital Toxoplasmosis. International Journal for Parasitology, 39, 1385-1394.
http://dx.doi.org/10.1016/j.ijpara.2009.04.003
[36] Hotez, P.J. (2008) Neglected Infections of Poverty in the United States of America. PLoS Neglected Tropical Diseases, 2, Article ID: e256, 1-11.
[37] Torgerson, R.P. and Mastroiacovo, P. (2013) The Global Burden of Congenital Toxoplasmosis: A Systematic Review. Bulletin of the World Health Organization, 91, 501-508.
http://dx.doi.org/10.2471/BLT.12.111732
[38] Wolf, A., Cowen, D. and Paige, B. (1939) Human Toxoplasmosis: Occurrence in Infants as an Encephalomyelitis Verification by Transmission to Animals. Science, 89, 226-227.
http://dx.doi.org/10.1126/science.89.2306.226
[39] Flegr, J., Preiss, M., Klose, J., Havlicek, J., Vitakova, M. and Kodym, P. (2003) Decreased Level of Psychobiological Factor Novelty Seeking and Lower Intelligence in Men Latently Infected with the Protozoan Parasite Toxoplasma gondii Dopamine, a Missing Link between Schizophrenia and Toxoplasmosis? Biological Psychology, 63, 253-268.
http://dx.doi.org/10.1016/S0301-0511(03)00075-9
[40] Fekadu, A., Shibre, T. and Cleare, A.J. (2010) Toxoplasmosis as a Cause for Behavior Disorders: Overview of Evidence and Mechanisms. Folia Parasitologica, 57, 105-113.
[41] Torrey, E.F., Bartko, J.J., Lun, Z.R. and Yolken, R.H. (2007) Antibodies to Toxoplasma gondii in Patients with Schizophrenia: A Meta-Analysis. Schizophrenia Bulletin, 33, 729-736.
http://dx.doi.org/10.1093/schbul/sbl050
[42] Pedersen, M.G., Mortensen, P.B., Norgaard-Pedersen, B. and Postolache, T.T. (2012) Toxoplasma gondii Infection and Self-Directed Violence in Mothers. JAMA Psychiatry, 69, 1123-1130.
http://dx.doi.org/10.1001/archgenpsychiatry.2012.668
[43] Zhang, Y., Traskman-Bendz, L., Janelidze, S., Langenberg, P., Saleh, A., Constantine, N., et al. (2012) Toxoplasma gondii Immunoglobulin G Antibodies and Nonfatal Suicidal Self Directed Violence. The Journal Clinical Psychiatry, 73, 1069-1076.
http://dx.doi.org/10.4088/JCP.11m07532
[44] Pearson, P.A., Piracha, A.R., Sen, H.A. and Jaffe, G.J. (1999) Atovaquone for the Treatment of Toxoplasma Retinochoroiditis in Immunocompetent Patients. Ophthalmology, 106, 148-153.
http://dx.doi.org/10.1016/S0161-6420(99)90021-0
[45] Hughes, W. and Oz, H.S. (1997) Successful Prevention and Treatment of Babesiosis with Atovaquone. In: Keusch, G., Ed., The Best of Infectious Diseases, Mosby-Year Book Inc., Saint Louis, 194-196.
[46] Zhou, B.H., Wang, H.W., Zhao, Z.S., Liu, M., Yan, W.C., Zhao, J., Zhang, Z. and Xue, F.Q. (2013) A Novel Serine/Threonine Protein Phosphatase Type 5 from Second Generation Merozoite of Eimeria tenella Is Associated with Diclazuril-Induced Apoptosis. Parasitology Research, 112, 1771-1780.
http://dx.doi.org/10.1007/s00436-013-3336-0